mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).
R-D HofheinzF HerrleT DechowL F von WeikersthalM WelslauS LettmaierC BurkartS KubickaL KochenK MerxK KrauseM EbertC RödelE FokasM GhadimiC ReissfelderT GaiserPublished in: ESMO open (2024)
In patients with locally advanced rectal cancer and MRI-defined low risk of local recurrence, neoadjuvant mFOLFOX6 + aflibercept was feasible and did not compromise surgery. Survival data were favorable in both arms, but pCR rates were not increased by the addition of aflibercept.
Keyphrases
- rectal cancer
- locally advanced
- phase ii study
- neoadjuvant chemotherapy
- age related macular degeneration
- contrast enhanced
- metastatic colorectal cancer
- magnetic resonance imaging
- minimally invasive
- free survival
- squamous cell carcinoma
- diffusion weighted imaging
- coronary artery bypass
- open label
- combination therapy
- magnetic resonance
- clinical trial
- data analysis
- lymph node
- acute coronary syndrome
- surgical site infection
- study protocol